• Explore /
  • Poster
  • / Plasma VEGF-a, angiopoietin-2 (ANG2) and soluble(s)TIE2 in patients (pts) with HER2-negative locally recurrent or metastatic breast cancer (LR/MBC) treated with first-line bevacizumab (A) and paclitaxel (T) without or with capecitabine (X).

Plasma VEGF-a, angiopoietin-2 (ANG2) and soluble(s)TIE2 in patients (pts) with HER2-negative locally recurrent or metastatic breast cancer (LR/MBC) treated with first-line bevacizumab (A) and paclitaxel (T) without or with capecitabine (X).

Abstract Poster

Authors

null

Siu W. Lam

VU University Medical Center, Amsterdam, Netherlands

Siu W. Lam , Steffen M. de Groot , Aafke H. Honkoop , Nienke M. Nota , A. Jager , Ankie M.T. van der Velden , Monique M.E.M. Bos , Sabine C. Linn , J. Van Den Bosch , Judith R. Kroep , J. J. Braun , Richard R. de Haas , Carolien H. Smorenburg , Hiltje de Graaf , Johanna Elisabeth A. Portielje , Maartje Los , Domingo de Gooyer , Harm van Tinteren , Epie Boven

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy

Track

Breast Cancer

Sub Track

Cytotoxic Chemotherapy

Clinical Trial Registration Number

NTR1348

Citation

J Clin Oncol 31, 2013 (suppl; abstr 1072)

DOI

10.1200/jco.2013.31.15_suppl.1072

Abstract #

1072

Poster Bd #

22G

Abstract Disclosures

Similar Posters

First Author: A. J. Montero

First Author: Zhichao Jiang

First Author: Mark Jesus Mendoza Magbanua

First Author: Christoph Rochlitz